MRGX4 Inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the MRGX4 receptor, a member of the Mas-related G-protein-coupled receptor (MRGPR) family. MRGX4, like other MRGPR receptors, is involved in modulating various sensory and physiological processes, particularly in the nervous system. These receptors are G-protein-coupled receptors (GPCRs), which play a crucial role in transducing extracellular signals into intracellular responses by activating associated G-proteins. MRGX4 Inhibitors function by binding to the MRGX4 receptor, either at the primary ligand-binding site (orthosteric site) or at an allosteric site that influences receptor function. This binding action interferes with the receptor's ability to undergo the conformational changes necessary to activate its associated G-protein, thereby blocking the signal transduction pathways that would normally be initiated by the receptor's activation.
The chemical design of MRGX4 Inhibitors is critical to their specificity and effectiveness. These inhibitors are typically structured to interact precisely with the MRGX4 receptor's transmembrane domains, where the ligand-binding sites are located. The inhibitors may contain hydrophobic regions that fit within the lipid-rich environment of the transmembrane domain, as well as polar or charged functional groups that form hydrogen bonds or ionic interactions with key amino acid residues within the receptor. This precise interaction is crucial for ensuring that the inhibitor can effectively prevent the receptor from activating its signaling pathways. Additionally, the solubility, stability, and bioavailability of these inhibitors are optimized to ensure that they can reach the MRGX4 receptor in its native cellular environment and maintain effective inhibition over time. The kinetics of binding, including how quickly and firmly the inhibitor binds to and dissociates from the receptor, are also important factors that influence the overall potency and duration of inhibition. Understanding the interactions between MRGX4 Inhibitors and the receptor is essential for gaining insights into the molecular mechanisms of GPCR signaling and the specific role that MRGX4 plays in sensory perception and other related cellular processes. This knowledge contributes to a deeper understanding of how MRGX4 modulates physiological responses at the molecular level.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine may downregulate MRGX4 by incorporating into DNA where it can inhibit DNA methyltransferase activity, leading to hypomethylation and potential suppression of the MRGX4 gene. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A could downregulate MRGX4 by inhibiting histone deacetylases, resulting in a more open chromatin structure around the MRGX4 gene, which could interfere with the initiation of transcription. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid has the potential to decrease MRGX4 expression through the inhibition of histone deacetylases, which may alter gene expression by changing chromatin conformation and limiting transcriptional activity. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A might reduce MRGX4 expression by binding to DNA in the MRGX4 gene promoter, hindering the binding of transcription factors necessary for MRGX4 gene transcription. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D could inhibit MRGX4 transcription by intercalating into DNA, obstructing the advancement of RNA polymerase along the MRGX4 gene during mRNA synthesis. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2′-Deoxycytidine may lead to decreased expression of MRGX4 by inhibiting DNA methyltransferases, which could result in the demethylation and silencing of the MRGX4 gene. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG 108 could potentially inhibit the expression of MRGX4 by blocking DNA methyltransferase enzymes, resulting in changes to the methylation pattern of the MRGX4 gene promoter. | ||||||
Hydralazine-15N4 Hydrochloride | 304-20-1 (unlabeled) | sc-490605 | 1 mg | $480.00 | ||
Hydralazine might lead to the downregulation of MRGX4 expression through its demethylating effects on DNA, thereby altering the expression of the MRGX4 gene. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
MS-275 may reduce MRGX4 expression by selectively inhibiting class I histone deacetylases, causing an increase in acetylated histones and potentially repressing MRGX4 gene transcription. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram could decrease MRGX4 expression by interfering with DNA methylation and histone acetylation processes, leading to alterations in the chromatin structure of the MRGX4 gene. | ||||||